Adverse events Study reports · adults with Major Depressive Disorder
It is very uncertain whether n3PUFAs changes adverse eventsStudy reports compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (4 to 6‐week · primary Raynaud's phenomenon
Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ depression · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ depression compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in adverse events (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at 12 months · people with inflammatory bowel disease
Antidepressants showed no clear difference in adverse events at 12 months compared with placebo (low certainty).
1 finding from 1 review
Adverse events Not reported · patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: candidiasis · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
It is very uncertain whether beclometasone changes adverse events: candidiasis compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (52–60 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (52–60 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events ‐ Miscarriage · patients with male subfertility
It is very uncertain whether antioxidants changes adverse events ‐ Miscarriage compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events ‐ pelvic pain · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ pelvic pain compared with placebo (very low certainty).
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
SAEs · adults with acute stroke
Iron chelator showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review
Specific adverse events: haemorrhage · cognitively healthy people in late life
Aspirin leads to higher adverse events (haemorrhage) compared with placebo (high certainty).
1 finding from 1 review
Adverse events ‐ weight loss · adults with Parkinson's disease
GLP‐1 receptor agonists showed no clear difference in adverse events ‐ weight loss compared with placebo (low certainty).
1 finding from 1 review